Back to Report Store Home

Chronic Respiratory Disease Drug Development Pipeline Review, 2018

  • Published: Nov-2018
  • Report Code: GBIHC050IDB
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Chronic Respiratory Disease Report Coverage

2.2 Asthma – Overview

2.3 Chronic Obstructive Pulmonary Disease (COPD) – Overview

2.4 Idiopathic Pulmonary Fibrosis – Overview

3 Therapeutics Development

3.1 Asthma

3.2 Chronic Obstructive Pulmonary Disease (COPD)

3.3 Idiopathic Pulmonary Fibrosis

4 Therapeutics Assessment

4.1 Asthma

4.2 Chronic Obstructive Pulmonary Disease (COPD)

4.3 Idiopathic Pulmonary Fibrosis

5 Companies Involved in Therapeutics Development

5.1 Asthma

5.2 Chronic Obstructive Pulmonary Disease (COPD)

5.3 Idiopathic Pulmonary Fibrosis

6 Dormant Projects

6.1 Asthma

6.2 Chronic Obstructive Pulmonary Disease (COPD)

6.3 Idiopathic Pulmonary Fibrosis

7 Discontinued Products

7.1 Asthma

7.2 Chronic Obstructive Pulmonary Disease (COPD)

7.3 Idiopathic Pulmonary Fibrosis

8 Product Development Milestones

8.1 Asthma

8.2 Chronic Obstructive Pulmonary Disease (COPD)

8.3 Idiopathic Pulmonary Fibrosis

9 Appendix

9.1 Methodology

9.2 Coverage

9.3 Secondary Research

9.4 Primary Research

9.5 Expert Panel Validation

9.6 Contact Us

9.7 Disclaimer

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$11985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards